Dendritic-cell-based immunotherapy combined with low-dose cyclophosphamide in patients with malignant pleural mesothelioma.
Phase of Trial: Phase I
Latest Information Update: 24 May 2016
At a glance
- Drugs Dendritic cell vaccine-Amphera (Primary) ; Cyclophosphamide
- Indications Mesothelioma
- Focus Adverse reactions
- 15 Nov 2010 Planned end date changed from 10 Jan 2011 to 1 Oct 2012 as reported by ClinicalTrials.gov.
- 15 Nov 2010 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
- 09 Nov 2009 New trial record